Old drugs, new uses: Drug repurposing in hematological malignancies

Vijay P. Kale, Hasan Habib, Robert Chitren, Milan Patel, Kartick C. Pramanik, Subash C. Jonnalagadda, Kishore Challagundla, Manoj K. Pandey

Research output: Contribution to journalReview articlepeer-review

29 Scopus citations


Discovery and development of novel anti-cancer drugs are expensive and time consuming. Systems biology approaches have revealed that a drug being developed for a non-cancer indication can hit other targets as well, which play critical roles in cancer progression. Since drugs for non-cancer indications would have already gone through the preclinical and partial or full clinical development, repurposing such drugs for hematological malignancies would cost much less, and drastically reduce the development time, which is evident in case of thalidomide. Here, we have reviewed some of the drugs for their potential to repurpose for treating the hematological malignancies. We have also enlisted resources that can be helpful in drug repurposing.

Original languageEnglish (US)
Pages (from-to)242-248
Number of pages7
JournalSeminars in Cancer Biology
StatePublished - Jan 2021

All Science Journal Classification (ASJC) codes

  • Cancer Research


Dive into the research topics of 'Old drugs, new uses: Drug repurposing in hematological malignancies'. Together they form a unique fingerprint.

Cite this